Celldex Therapeutics buy Morgan Stanley
Start price
20.03.25
/
50%
€18.40
Target price
20.03.26
€42.18
Performance (%)
26.09%
Price
12.12.25
€23.60
Summary
This prediction is currently active. The prediction currently has a performance of 26.09%. This prediction currently runs until 20.03.26. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Celldex Therapeutics | -6.349% | -6.349% |
| iShares Core DAX® | 0.734% | 1.458% |
| iShares Nasdaq 100 | -2.686% | -0.146% |
| iShares Nikkei 225® | -2.261% | -2.729% |
| iShares S&P 500 | -1.346% | 0.467% |
Comments by Morgan_Stanley for this prediction
In the thread Celldex Therapeutics diskutieren
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Stopped prediction by Morgan_Stanley for Celldex Therapeutics
Celldex Therapeutics
Start price
Target price
Perf. (%)
€16.30
09.05.25
09.05.25
€38.34
09.05.26
09.05.26
42.33%
12.12.25
12.12.25
